<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812784</url>
  </required_header>
  <id_info>
    <org_study_id>PI2015_843_0022</org_study_id>
    <nct_id>NCT02812784</nct_id>
  </id_info>
  <brief_title>Can Nephrocheck™ Predict the Reversibility of Early, Acute Kidney Injury During Septic Shock?</brief_title>
  <acronym>AKI-CHECK</acronym>
  <official_title>Can Nephrocheck™ Predict the Reversibility of Early, Acute Kidney Injury During Septic Shock?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <brief_summary>
    <textblock>
      Patients with septic shock in the intensive care unit have an elevated risk of developing&#xD;
      acute kidney injury (AKI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with septic shock in the intensive care unit have an elevated risk of developing&#xD;
      acute kidney injury (AKI). AKI is an independent factor for mortality. Interventions that&#xD;
      limit the worsening of renal function might have an impact on the mortality rate in these&#xD;
      patients. Given the absence of validated pharmacological treatments for limiting the&#xD;
      progression of AKI or for accelerating recovery from AKI, early intervention and the&#xD;
      restoration of the glomerular filtration rate (GFR) in this context of hemodynamic change&#xD;
      during the initial phase of septic shock might improve the patients' prognosis. One major&#xD;
      challenge is therefore how to determine whether or not the AKI is reversible. The&#xD;
      best-studied biomarkers (NGAL and KIM 1) have little discriminant power in septic patients&#xD;
      because of their poor specificity or unsuitable kinetics for very early diagnosis. The&#xD;
      combination of urine assays for tissue inhibitor of metalloproteinase 2 (TIMP2) and&#xD;
      insulin-like growth factor binding protein 7 (IGFBP7) has shown good diagnostic performance&#xD;
      for the very early detection of the risk of developing AKI in the following 12 hrs. Urine&#xD;
      levels of these two markers specifically reflect damage to kidney tubules. Moreover, the&#xD;
      levels appear to be strongly correlated with the severity of tubule damage. Thus, one can&#xD;
      reasonably hypothesize that measurement of these markers in the very early stages of septic&#xD;
      shock might determine the presence and severity of kidney tubule damage. A threshold (yet to&#xD;
      be defined) would help to differentiate between (i) transient, non-severe injury and (ii)&#xD;
      injury that is already too severe to be reversible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 16, 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>KDIGO classification</measure>
    <time_frame>72 hours</time_frame>
    <description>predictive value of Nephrocheck™ with regard to the reversibility of AKI, defined as the recovery of normal renal function (KDIGO 0) in the 72 hours following inclusion</description>
  </primary_outcome>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Heading</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nephrocheck TM</intervention_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with Septic shock (according to Bone's criteria) within 4 hours of introduction of&#xD;
        catecholamines&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or over&#xD;
&#xD;
          -  Septic shock (according to Bone's criteria) within 4 hours of introduction of&#xD;
             catecholamines&#xD;
&#xD;
          -  AKI, characterized by a KDIGO score ≥ 1&#xD;
&#xD;
          -  Social security coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AKI requiring emergency RRT (in the critical care physician's opinion).&#xD;
&#xD;
          -  Anuria&#xD;
&#xD;
          -  Stage 4-5 chronic kidney failure with a GFR below 30 ml/min.&#xD;
&#xD;
          -  Rapidly progressing renal disorders (glomerulonephritis, HUS, blockage, etc.)&#xD;
&#xD;
          -  Obstructive AKI&#xD;
&#xD;
          -  Probable glomerular damage (nephritic syndrome, nephrotic syndrome, chronic&#xD;
             glomerulonephritis)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Legal guardianship or lack of social security coverage.&#xD;
&#xD;
          -  Cardiocirculatory arrest&#xD;
&#xD;
          -  Life expectancy &lt;48 hours.&#xD;
&#xD;
          -  Child C cirrhosis&#xD;
&#xD;
          -  Prior occurrence of AKI during the current hospital stay&#xD;
&#xD;
          -  Transplantation&#xD;
&#xD;
          -  Subject participating in another study with an exclusion period ongoing at the time of&#xD;
             the pre-inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien MAIZEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien MAIZEL, Md, PhD</last_name>
    <phone>+33 3 22 08 78 07</phone>
    <email>maizel.julien@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien MAIZEL, MD, PhD</last_name>
      <phone>+33 3 22 08 78 07</phone>
      <email>maizel.julien@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Avranches-Granville</name>
      <address>
        <city>Avranches</city>
        <zip>50300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric GODDE, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Cahors</name>
      <address>
        <city>Cahors</city>
        <zip>46000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim CHAOUKI, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Dax</name>
      <address>
        <city>Dax</city>
        <zip>40100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maude ANDRIEU, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Marc Jacquet</name>
      <address>
        <city>Melun</city>
        <zip>77000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe VINSONNEAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Mont-de-Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel PASCAL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34172</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kada KLOUCHE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Paris-Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoît MISSET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René ROBERT, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe MARIAT, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Salon-de-provence</name>
      <address>
        <city>Salon-de-provence</city>
        <zip>13300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hicham BAHLOUL, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nephrocheck™</keyword>
  <keyword>acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

